Malnutrition outweighs the effect of the obesity paradox

Suriya Prausmüller1, Gregor Heitzinger1, Noemi Pavo1, Georg Spinka1, Georg Goliasch1, Henrike Arfsten1, Cornelia Gabler2, Guido Strunk3, Christian Hengstenberg1, Martin Hülsmann1* & Philipp E. Bartko1

1Division of Cardiology, Department of Internal Medicine, II, Medical University of Vienna, Vienna, Austria; 2IT Systems and Communications, Medical University of Vienna, Vienna, Austria; 3Complexity Research, Vienna, Austria

Abstract

Background High body mass index (BMI) is paradoxically associated with better outcome in patients with heart failure (HF). The effects of malnutrition on this phenomenon across the whole spectrum of HF have not yet been studied.

Methods In this observational study, patients were classified by guideline diagnostic criteria to one of three heart failure subtypes: reduced (HFrEF), mildly reduced (HFmrEF), and preserved ejection fraction (HFP EF). Data were retrieved from the Viennese-community healthcare provider network between 2010 and 2020. The relationship between BMI, nutritional status reflected by the prognostic nutritional index (PNI), and survival was assessed. Patients were classified by the presence (PNI < 45) or absence (PNI ≥ 45) of malnutrition.

Results Of the 11 995 patients enrolled, 6916 (58%) were classified as HFpEF, 2809 (23%) HFmrEF, and 2270 HFrEF (19%). Median age was 70 years (IQR 61–77), and 67% of patients were men. During a median follow-up time of 44 months (IQR 19–76), 3718 (31%) of patients died. After adjustment for potential confounders, BMI per IQR increase was independently associated with better survival (adj. hazard ratio [HR]: 0.91 [CI 0.86–0.97], P = 0.005), this association remained significant after additional adjustment for HF type (adj. HR: 0.92 [CI 0.86–0.98], P = 0.011). PNI was available in 10 005 patients and lowest in HFrEF patients. PNI was independently associated with improved survival (adj. HR: 0.96 [CI 0.95–0.97], P < 0.001); additional adjustment for HF type yielded similar results (adj. HR: 0.96 [CI 0.96–0.97], P < 0.001). Although obese patients experienced a 30% risk reduction, malnutrition at least doubled the risk for death with 1.8- to 2.5-fold higher hazards for patients with poor nutritional status compared with normal weight well-nourished patients.

Conclusions The obesity paradox seems to be an inherent characteristic of HF regardless of phenotype and nutritional status. Yet malnutrition significantly changes trajectory of outcome with regard to BMI alone: obese patients with malnutrition have a considerably worse outcome compared with their well-nourished counterparts, outweighing protective effects of high BMI alone. In this context, routine recommendation towards weight loss in patients with obesity and HF should generally be made with caution and focus should be shifted on nutritional status.

Keywords Malnutrition; Obesity paradox; Heart failure; PNI

© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Cachexia, Sarcopenia and Wasting Disorders. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Introduction

Obesity as a well-established risk factor is known to greatly increase risk for the development of cardiovascular disease including heart failure (HF), setting obesity as the world’s leading preventable risk factor for early death. Paradoxically, once a patient develops HF, high body mass index (BMI) seems to confer a survival advantage compared with leaner individuals, a phenomenon commonly referred to as the ‘obesity paradox’. Several explanations have been put forth to explain this association. To date, it is not entirely clear whether this is a true phenomenon or a consequence of methodological limitations such as confounding or reverse causation. Earlier appearance of symptoms in obese individuals at the one hand and disease-associated weight loss, smoking status, and muscle wasting, on the other, have been identified as possible reasons for the obesity paradox. Although often ignored, malnutrition is highly prevalent among patients with HF and is associated with poor prognosis, prolonged hospital stays, and poor quality of life especially at advanced disease stages. Numerous studies have outlined the importance of nutritional assessment in clinical practice especially in target groups at risk as HF. Importantly, malnutrition is not only common in underweight/lean individuals but is also common in those who are overweight, obese, or even morbidly obese. Emerging data imply a close link between malnutrition and markers of systemic inflammation generating a hypothesis that increasing adiposity may be protective against the malnutrition–inflammation–cachexia complex which is characteristic for advanced stages of chronic HF. In recent years, several nutritional screening tools have been advocated to assess nutritional status in HF patients. The Prognostic Nutritional Index (PNI) provides a simple and objective tool that has been widely used for evaluating nutritional status.

Previous studies investigating the impact of obesity were largely performed in patients with HF with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF) or in chronic HF regardless of ejection fraction. The relationship between outcome and BMI in patients with HF and mildly reduced ejection fraction (HFmrEF) is less clear and has rarely been addressed. Therefore, this study aims (i) to explore the relationship between nutritional status and BMI across the whole spectrum of HF and (ii) to investigate the impact of nutritional status, reflected by PNI, on the obesity paradox across HF phenotypes.

Materials and methods

Study population

A single centre, retrospective observational study design has been followed. Patients with chronic HF were enrolled between 2010 and 2020 at the Medical University of Vienna. Detailed study selection criteria have been described before. Briefly, medical health records and echocardiography database were used to identify patients with HFpEF, HFmrEF, and HFrEF following algorithms that comply with the current guideline diagnostic criteria. This database includes inpatients and outpatients from the Medical University of Vienna. In accordance with the current guidelines, the following algorithms were applied to identify patients with the respective HF phenotype:

In patients with mildly reduced or preserved left ventricular function (ejection fraction above 40%), at least one of the following criteria were required: structural heart disease as identified by left atrial enlargement and/or left ventricular hypertrophy, or diastolic dysfunction. Moreover, the presence of elevated N-terminal pro brain-type natriuretic peptide (NT-proBNP) values (>125 pg/mL) and symptoms as well as signs of HF were mandatory for study inclusion. HF with a significant reduction in left ventricular systolic function, that is, left ventricular ejection fraction <40%, was designated as HFrEF.

Echocardiographic exams with missing values of interest and patients with primary valve disease were excluded from the study. Likewise, patients without signs and symptoms of HF, with NT-proBNP values below 125 pg/mL and without measurement of height and weight, were excluded from the analysis. The final study group consisted of 11 995 individuals stratified according to the HF phenotypes.

Targeted keyword search and designated coding from the International Statistical Classification of Diseases (ICD) and Related Health Problems allowed the collection of medical history and laboratory parameters from the electronic local health record database. The process for assigning diagnostic codes is standardized at the Medical University of Vienna. At the time of patient discharge or outpatient presentation, healthcare professionals assign ICD-codes based on newly diagnosed diseases and the patient’s medical history. Routine laboratory parameters were analysed from venous blood samples according to the local laboratory’s standard procedure. The study was approved by the institutional ethics review board of the Medical University of Vienna (IRBNr: 2137) with a waiver for informed consent.

Body mass index

Body mass index was calculated as weight in kilograms divided by height in meters squared (kg/m²). Subjects were stratified according to BMI levels <18.5, ≥18.5–24.9, ≥25.0–29.9, 30.0–34.9, and ≥35.0 kg/m². To study the relationship between BMI and PNI, the following BMI strata were built: <25, 25–30, 30–35, and ≥35 kg/m².

DOI: 10.1002/jcsm.12980
Prognostic nutritional index

Albumin levels and total lymphocyte counts were routinely measured during outpatient visits or on admission. The nutritional status was assessed by the PNI according to the following formula: albumin (g/L) + 5 × total lymphocyte count × 10⁹/L. Lower PNI scores indicate worse nutritional status. The optimal threshold value of the PNI score to identify individuals at risk was 46.5.

Endpoints and follow-up

The primary endpoint was defined as all-cause mortality and was assessed via record linkage with the Austrian Death Registry.

Echocardiographic assessment

Standard transthoracic echocardiograms (2D, Doppler) examinations were performed using commercially available equipment (Vivid E7 and E9, GE Healthcare, Chicago, IL and Acuson S2000, Siemens, Berlin, Germany) according to

| Table 1  | Baseline characteristics, laboratory, and echocardiographic parameters in the overall cohort and according to heart failure phenotypes |
|----------|-------------------------------------------------------------------------------------------------------------|
|          | Overall cohort (n = 11 995) | HFpEF (n = 6916) | HFrEF (n = 2809) | HFrEF (n = 2270) | P-value |
| Clinical characteristics | | | | | |
| Age, years (IQR) | 70 (61–77) | 71 (63–78) | 70 (60–77) | 67 (57–75) | <0.001 |
| Female, n (%) | 4011 (33) | 2826 (41) | 660 (23) | 525 (23) | <0.001 |
| BMI (IQR) | 27.5 (24.5–31.1) | 27.7 (24.6–31.5) | 27.5 (24.6–30.8) | 26.8 (23.9–30.4) | <0.001 |
| <22.5 kg/m², n (%) | 1328 (11) | 725 (10) | 275 (10) | 328 (14) | 0.455 |
| 22.5–24.9 kg/m², n (%) | 2252 (19) | 1264 (18) | 523 (19) | 465 (20) | 0.003 |
| 25.0–29.9 kg/m², n (%) | 4640 (39) | 2610 (38) | 1164 (41) | 866 (38) | <0.001 |
| ≥30.0–34.9 kg/m², n (%) | 2489 (21) | 1500 (22) | 588 (21) | 401 (18) | 0.034 |
| ≥35 kg/m², n (%) | 1286 (11) | 817 (12) | 259 (9) | 210 (9) | <0.001 |
| Co-morbidities | | | | | |
| Hypertension, n (%) | 7291 (61) | 4272 (62) | 1762 (63) | 1257 (55) | <0.001 |
| Hyperlipidaemia, n (%) | 4118 (34) | 2231 (31) | 1107 (39) | 780 (34) | <0.001 |
| Diabetes, n (%) | 3097 (26) | 1702 (25) | 738 (26) | 657 (29) | 0.002 |
| Coronary artery disease, n (%) | 5899 (49) | 2825 (41) | 1744 (62) | 1330 (59) | <0.001 |
| Atrial fibrillation, n (%) | 3600 (30) | 2092 (30) | 810 (29) | 698 (31) | 0.007 |
| Chronic obstructive pulmonary disease, n (%) | 1590 (13) | 898 (13) | 353 (13) | 339 (15) | <0.001 |
| Peripheral artery disease, n (%) | 2892 (24) | 1656 (24) | 695 (25) | 541 (24) | <0.001 |
| Laboratory parameters | | | | | |
| Haematocrit, % (IQR) | 38 (33–42) | 38 (33–42) | 38 (33–42) | 39 (34–43) | <0.001 |
| Blood urea nitrogen, mg/dL (IQR) | 18.4 (14.0–25.5) | 17.9 (13.7–24.5) | 18.3 (14.0–25.2) | 20.7 (15.5–30.2) | <0.001 |
| BChE, kU/I (IQR) | 6.5 (5.0–7.9) | 6.6 (5.2–8.0) | 6.5 (5.1–7.9) | 5.9 (4.4–7.4) | <0.001 |
| Albumin, g/L (IQR) | 39.2 (35.1–42.4) | 39.5 (35.4–42.6) | 39.1 (35.0–42.2) | 38.5 (34.5–42.1) | <0.001 |
| LDL cholesterol, mg/dL (IQR) | 91.6 (67.6–119.4) | 93.2 (69.8–121.4) | 90.8 (66.2–120.4) | 85.8 (63.0–112.0) | <0.001 |
| Total lymphocyte count, ×10⁹/L (IQR) | 7.4 (6.0–9.3) | 7.3 (5.9–9.0) | 7.6 (6.2–9.6) | 7.8 (6.4–9.5) | <0.001 |
| NT-proBNP, pg/mL (IQR) | 1128 (405–3163) | 749 (321–1893) | 1570 (580–3796) | 3558 (1529–8088) | <0.001 |
| Echocardiographic parameters | | | | | |
| Left atrial diameter, mm (IQR) | 58 (54–64) | 58 (54–63) | 59 (54–64) | 61 (55–67) | <0.001 |
| Left ventricular end-diastolic diameter, mm (IQR) | 47 (43–52) | 45 (41–48) | 49 (45–54) | 57 (51–62) | <0.001 |
| Right atrial diameter, mm (IQR) | 57 (52–63) | 56 (52–62) | 56 (52–62) | 58 (51–65) | <0.001 |
| Right ventricular end-diastolic diameter, mm (IQR) | 34 (30–37) | 33 (30–37) | 34 (30–47) | 35 (31–40) | <0.001 |
| Right ventricular function | | | | | |
| Moderately reduced, n (%) | 1519 (13) | 352 (5) | 347 (12) | 820 (36) | <0.001 |
| Severe reduced, n (%) | 299 (3) | 48 (1) | 32 (1) | 219 (10) | <0.001 |
| Mitral regurgitation (severe), n (%) | 1178 (10) | 292 (4) | 290 (10) | 596 (26) | <0.001 |
| Systolic pulmonary artery pressure, mmHg (IQR) | 44 (37–54) | 43 (36–54) | 44 (36–54) | 48 (39–59) | <0.001 |

Continuous variables are given as median and interquartile range (IQR), and counts are given as numbers and percentages (%). BChE, butyrylcholinesterase; BMI, body mass index; HFrEF, heart failure with mildly reduced ejection fraction; HFrEF, heart failure with preserved ejection fraction; HFpEF, heart failure with reduced ejection fraction; LDL, low density lipoprotein; NT-proBNP, N-terminal pro-brain-type natriuretic peptide.
Cardiac morphology was assessed in standard four and two chamber views. Left ventricular systolic function was graded according to ejection fraction cut-offs. According to the local laboratory standard, left ventricular ejection fraction cut-offs were ≥50% corresponding for HFP EF, 40–49% for HFmrEF, and <40% for HFrEF. Semiquantitative assessment of right heart function was performed by experienced readers using multiple acoustic windows graded as normal, mild, mild-to-moderate, moderate, moderate-to-severe, and severe. Valvular regurgitation was quantified using an integrated approach and graded as none, mild, mild-to-moderate, moderate, moderate-to-severe, and severe. Systolic pulmonary artery pressures were calculated by adding the peak tricuspid regurgitation systolic gradient to the estimated central venous pressure.

**Statistical analysis**

Continuous data are expressed as median and interquartile range (IQR) and categorical data as count and percentages. Comparison between groups was performed by the Kruskal–Wallis test, Mann–Whitney U test, and the Fisher’s exact test as appropriate. Cox proportional hazard regression analysis was applied to assess the impact of BMI and the PNI score on outcome, and the results are presented as hazard ratio (HR) with 95% confidence interval (CI). The covariates presented in Table 1 (excluding echocardiographic parameters) with P-values <0.10 in the univariate analysis were considered significant for entry in the multivariate analysis. These variables were age, history of hypertension, diabetes, coronary artery disease, atrial fibrillation, chronic obstructive pulmonary disease, peripheral artery disease, haematocrit, blood urea nitrogen (BUN), NT-proBNP, cholinesterase, albumin, low density lipoprotein, and lymphocyte count. For multivariate testing of PNI, albumin and lymphocyte count were excluded from the model. To assess whether associations were independent of HF phenotype, the model was additionally adjusted for HF type. Restricted cubic spline curves were generated to illustrate the association of BMI with outcome. Time-to-event data are presented as Kaplan–Meier curves. Log-rank tests were used to compare survival between groups. Additional subgroup analysis was conducted to investigate the impact of BMI on outcome in prespecified subgroups. Two-sided P-values <0.05 were considered statistically significant. Statistical analysis was performed using SPSS software (IBM SPSS, Chicago, Illinois, USA) version 24 and RStudio (R Foundation for Statistical Computing, Vienna, Austria) version 1.3.1073.

![Image](image-url)

**Figure 1** The obesity paradox across the spectrum of heart failure (HF). Distribution of body mass index (BMI) (left), the hazard ratios (HR) for all-cause mortality with 95% confidence intervals (CI) according to the BMI strata (middle) and restricted spline curves examining the association of BMI and outcome (right) are shown for heart failure with preserved ejection fraction (HFP EF), heart failure with mildly reduced ejection fraction (HFmrEF), and heart failure with reduced ejection fraction (HFrEF).
Results

Study population

Of the 11 995 patients enrolled, 6916 (58%) had HFpEF, 2809 (23%) HFmrEF, and 2270 HFrEF (19%). Median age was 70 years (IQR: 61–77), and the majority of patients were men (n = 7984, 67%). The most common comorbidity was hypertension with 61% (n = 7219). Individuals with HFrEF had significantly, but clinically not meaningful, lower BMI values than the HFmrEF and HFpEF group (26.8 [IQR 23.9–30.4], 27.5 [IQR 24.6–30.8], 27.7 [IQR 24.6–31.5], respectively; P = 0.001). Table 1 shows the baseline characteristics of the overall cohort and for the respective HF subtypes.

Impact of body mass index on outcome for the overall cohort and across the heart failure spectrum

During a median follow-up time of 44 months (IQR 19–76), a total of 3718 (30%) deaths were observed. Our results demonstrate a near U-shaped association between BMI and mortality for the overall cohort of HF with an inverse relationship in individuals with a BMI < 35 kg/m² (Supporting Information, Figure S1). BMI was consistently associated with lower risk for all-cause mortality in both the HF phenotypes and various subgroups as shown in Figures 1 and 2. Univariate Cox regression analysis revealed a uniformly significant inverse association between BMI per IQR and all-cause mortality for all HF types (HFpEF: HR: 0.83 [CI 0.78–0.87], P < 0.001, HFmrEF: HR: 0.70 [CI 0.63–0.77], P < 0.001 and HFrEF: HR: 0.83 [0.76–0.91, P < 0.001]; P-for-interaction: 0.420). Significant interactions were observed for BMI and diabetes, kidney function, and age with a more pronounced association in patients without diabetes (no diabetes: HR: 0.71 [0.67–0.75], P < 0.001; diabetes: HR: 0.80 [CI 0.75–0.86], P < 0.001; P-for-interaction: 0.005), with lower BUN levels (BUN <18.4 mg/dL: HR: 0.74 [CI 0.68–0.79], P < 0.001; BUN ≥18.4 mg/dL: HR: 0.82 [CI 0.78–0.87], P < 0.001; P-for-interaction: 0.023), and in older individuals (age <65 years: HR: 0.93 [CI 0.86–1.01], P = 0.117; age ≥65 years: HR: 0.80 [CI 0.76–0.84], P < 0.001; P-for-interaction: 0.002). There was no significant interaction between BMI and sex, ischaemic heart disease, hypertension, inflammation, liver function, and cholesterol metabolism. In multivariate analysis, BMI per IQR was independently associated with better survival (adj. HR: 0.91 [CI 0.86–0.97], P = 0.005), and this association remained significant after additional adjustment for HF type (adj. HR: 0.92 [CI 0.86–0.98], P = 0.011).

The Kaplan–Meier estimates for the overall survival at 4 years differed significantly between the HF groups with worse survival in the HFrEF population (74.2% for HFpEF, 73.5% for HFmrEF, and 66.4% for HFrEF; log-rank P < 0.001). Cubic spline modelling and the relative hazards for BMI strata and outcome for the respective HF phenotypes.

![Figure 2](https://example.com/figure2.png)
are depicted in Figure 1. The association of increasing BMI values and favourable outcome was consistent across all HF phenotypes. Compared with patients with BMI levels between 22.5 and 24.9 kg/m² (reference group), patients in the lower BMI category (<22.5 kg/m²) had significant worse outcome, while individuals in higher BMI categories (>25 kg/m²) had a significant survival advantage independent of HF phenotype.

Impact of prognostic nutritional index on the obesity paradox

Data for calculation of the PNI score were available in 10,005 patients. Median PNI was 46.9 (IQR 41.8–51.3) in the overall cohort. Patients with HFrEF had significantly lower PNI scores compared with individuals with HFrEF but not HFrEF (46.0 [IQR 40.8–51.3] vs. 47.2 [IQR 42.2–51.5], \( P < 0.001 \); vs. 46.8 [IQR 41.8–51.0], \( P = 0.070 \)) (Figure 3).

In all three HF phenotypes, high PNI was associated with improved survival in the univariate analysis (HFrEF: HR: 0.93 [CI 0.92–0.93], HFrEF: HR: 0.92 [CI 0.91–0.93], HFrEF: HR: 0.93 [CI 0.92–0.94]; \( P < 0.001 \) for all). After multivariate adjustment, PNI remained significant to predict outcome (adj. HR: 0.96 [CI 0.95–0.97], \( P < 0.001 \)), additionally adjusting for HF type yielded similar results (adj. HR: 0.96 [CI 0.96–0.97], \( P < 0.001 \)). Figure 4 illustrates the relationship between BMI and outcome depending on malnutrition status for the overall cohort and HF phenotypes. Although a higher BMI was associated with generally favourable outcome in both PNI groups separately (Supporting Information, Table S1), the hazard for patients with poor nutritional status (low PNI) was 1.8- to 2.5-fold higher compared with the reference group of normal weight high PNI patients. Kaplan–Meier analysis confirmed the survival advantage in obese patients with high PNI, whereas the outcome becomes less favourable with decreasing BMI and especially low PNI for all HF phenotypes.

Discussion

Main findings

This study reinforces the evidence of an obesity paradox across HF regardless of sex, ischaemic aetiology of HF and especially HF phenotype with similar findings for HFrEF, HFrEF, and HFrEF in a comprehensive cohort of HF patients. Our data underscore the importance of nutritional status in relation to the obesity paradox. While increasing BMI is indeed associated with better outcomes in both normal and malnourished patients, obesity alone cannot outbalance malnutrition, with worse prognosis observed in obese but malnourished patients compared with normal weight patients with normal nutritional index.

Whether a low PNI already reflects malnutrition within the scope of a proinflammatory predisposition marking a more advanced state of disease or is a modifiable factor remains to be investigated. The results, however, encourage clinicians to further assess nutritional status in otherwise obese HF patients to identify malnourished individuals with an intrudingly poor prognosis, which seems contra-intuitive.

Obesity paradox in heart failure

An inverse association between outcome and BMI has been repeatedly demonstrated in individuals with HFrEF and HFrEF. To the best of our knowledge, there is only one study reporting the presence of the obesity paradox in HFrEF with 947 individuals.12 With 11,995 patients enrolled (58% HFrEF, 23% HFrEF, and 19% HFrEF), the current report presents the largest study so far confirming the obesity paradox irrespective of HF phenotype.

The presence of the obesity paradox in HF should clearly not be seen as a promotion of obesity in the general population or individuals without cardiovascular disease; however, recommendations for patients with established disease are not clear. Indeed, assessment of BMI alone may not capture the whole picture of metabolic health as it poorly reflects body composition and metabolic capacity or their trajectories. Therefore, caution should be exercised when recommending weight loss in patients considering only BMI. A number of hypotheses have been drawn to decipher the inverse association of BMI and outcome. The resilient protection of high BMI in patients with HF may be explained by greater metabolic reserve, re-
duced sympathetic activity, attenuated response to neuroendocrine stimuli, and less catabolic state.\textsuperscript{4,19} In addition, adipose tissue may attenuate inflammatory responses through synthesis of beneficial adipokines.\textsuperscript{20} The endotoxin/lipid hypothesis suggests that higher circulating lipoproteins in obese patients may enhance endotoxin-scavenging activity, resulting in lower proinflammatory cytokine production.\textsuperscript{21} In light of these considerations, excess body weight is thought to counteract the catabolic effects of HF and thus provide a metabolic cushion to mitigate disease progression.

However, because data on the obesity paradox mostly emerged from observational studies, bias underlying the paradoxical association such as confounding or reverse causation need to be considered. This wide term includes confounding by pre-existing weight loss or other predictors of low body weight (e.g. stage and grade of disease, malnutrition, and smoking status) which in turn increase the risk of adverse outcome.\textsuperscript{22} Irrespective of that, one may also argue that lower BMI remains a surrogate for advanced disease stage.

Figure 4 (Left) Hazard ratios (HR) for all-cause mortality with 95% confidence intervals are shown for body mass index (BMI) in relation to low and high prognostic nutritional index (PNI). (Right) Kaplan–Maier curves showing all-cause mortality for prespecified BMI groups stratified by nutritional status. The $P$-value of a log-rank test for trend is shown for each plot.
Malnutrition is common in patients at advanced disease stage and carries poor prognosis.\(^\text{23}\) It is defined as a metabolic state resulting from a chronic imbalance between anabolism and catabolism leading to loss of appetite, malabsorption, inflammation, muscle wasting, and cachexia. In HF, chronic congestion accompanied by gastrointestinal congestion leads to decreased nutrient intake further driving muscle wasting.\(^\text{23,24}\) Disturbed gut perfusion and impaired microcirculation of the intestine results in local oedema, abnormal mucosal permeability, and increased endotoxin absorption further promoting a proinflammatory milieu.\(^\text{25}\) The consequent inflammation is considered to be a key driver of cardiac cachexia representing the hallmark of end-stage chronic HF.\(^\text{26}\) To date, there are no clear assessment criteria, universally accepted definitions, or standardized methods for determining nutritional status in patients with HF. PNI calculated with serum albumin concentration and total lymphocyte count presents an easy and objective screening tool to detect cardiometabolic derangements in HF that may allow early detection of both malabsorption and inflammatory disturbances. Numerous reports have demonstrated that albumin is a strong predictor for outcome across the spectrum of HF and provides comparable prognostic information to simple or multidimensional malnutrition tools.\(^\text{27,28}\) However, as albumin concentration is known to be affected by several non-nutritional factors such as hydration state, liver dysfunction, capillary permeability, nephrotic syndrome, infection, and malignancies, the use of albumin alone may not provide a comprehensive and accurate reflection of nutritional status. Lymphocyte count constitutes another determining factor of the PNI score. Nutritional deprivation is commonly associated with impaired immune response leading to lymphocyte depletion.\(^\text{29}\) Previous reports have shown that total lymphocyte count correlates with various established nutritional assessment tools.\(^\text{30}\) Therefore, combining serum albumin levels and the lymphocyte count to create the PNI may be useful as a screening tool for patients at risk of malnutrition who may benefit from a more detailed nutritional assessment. Earlier reports have shown that low PNI is independently associated with poor outcome in patients with either HFrEF or HFrEF and in chronic HF regardless of ejection fraction.\(^\text{8–11}\) To our knowledge, there are no previous studies investigating PNI specifically in patients with HFmrEF. Clearly, our data demonstrate that a substantial proportion of patients with HF, especially HFrEF, are at great risk for malnutrition. Notably, nearly one in two patients with HFrEF had signs of malnutrition. This finding appears consistent with earlier studies reporting a prevalence to be as high as 69% in some HF populations.\(^\text{9}\) Moreover, the present study demonstrates that nutritional status assessed by PNI is an independent predictor of mortality across the spectrum of HF, now embracing also HFmrEF.

### The impact of malnutrition on the obesity paradox

Obese patients in the general population are recommended to lose weight; however, these recommendations become uncertain for individuals with obesity and concomitant HF.\(^\text{31}\) Importantly, BMI alone will not distinguish between metabolically healthy and metabolically unhealthy individuals. Although our data confirm the observation of protective effects of BMI on outcome in individuals with HF, a closer look incorporating signs of malnutrition revealed that increased body weight cannot reverse the negative impact of malnutrition. While obese patients experience a 30% risk reduction, malnutrition at least doubles the risk for death.

Patients with low BMI and poor nutritional status represent a group of patients with diminishing metabolic reserve and with great risk for cardiac cachexia or already established cardiac cachexia. Undoubtedly, this group of patients are at extremely high risk for adverse outcome and should be closely monitored in daily routine practice. The data of this report however also imply that nutritional assessment is also essential in obese patients, because once signs of malnutrition become apparent, the risk of fatal events increases dramatically although obesity is suggestive for better outcomes based on the obesity paradox.

### Limitations

The results of our study should be interpreted in light of its limitations. First, based on the retrospective observational study design, the risk of bias and residual confounding cannot be completely ruled out, although we attempted to adjust for the confounding factors. The observational nature of this report allows us to demonstrate associations, but no inferences can be made about causal relationships. Second, medical history data were derived from the health care provider information system, using codes from the International Statistical Classification of Diseases and Related Health Problems, which could have led to a misclassification and/or underestimation of comorbid conditions. Third, left ventricular ejection fraction could not be measured quantitatively in all patients using biplane Simpson’s method, due to the limitations inherent to the method such as poor image quality, dyssynchrony, regional wall motion abnormalities, and foreshortening. Fourth, we did not evaluate measures of frailty, which may be useful to explain the relationship between being underweight and all-cause mortality especially in the elderly age group.

### Conclusion

The obesity paradox applies for the whole spectrum of HF irrespective of phenotype, that is, HFrEF, HFmrEF, and HFrEF.
Nonetheless, the prognosis in obese patients varies greatly depending on the status of malnutrition, which underlines the importance of additional nutritional assessment in lean, but especially in obese patients for individual patient risk stratification.

**Funding**

This work was supported by the grant from the Austrian Science Fund (KLI 700-B30).

**Acknowledgements**

All authors certify that they have complied with the ethical guidelines for authorship and publishing in the *Journal of Cachexia, Sarcopenia, and Muscle.*

**References**

1. Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. *N Engl J Med* 2002; 347:305–313.

2. Padwal R, McAlister FA, McMurray JJV, Cowie MR, Rich M, Pocock S, et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. *Int J Obes (Lond)* 2014;38:1110–1114.

3. Yu X-Y, Song P, Zou M-H. Obesity paradox and smoking gun: a mystery of statistical confounding? *Circ Res* 2018;122:1642–1644.

4. Livi CI, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. *J Am Coll Cardiol* 2009;53:1925–1932.

5. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. *J Cachexia Sarcopenia Muscle* 2010;1:1–5.

6. Aquilani R, Opasich C, Verri M, Boschi F, Febo O, Pasini E, et al. Is nutritional intake adequate in chronic heart failure patients? *J Am Coll Cardiol* 2003;42:1218–1223.

7. Agra Bermejo RM, González Ferreiro R, Varela Román A, Gómez Otero I, Kreidieh O, Conde Sabarís P, et al. Nutritional status is related to heart failure severity and hospital readmissions in acute heart failure. *Int J Cardiol* 2017;230:108–114.

8. Sze S, Pellicori P, Kazmi S, Rigby A, Cleland JGF, Wong K, et al. Prevalence and prognostic significance of malnutrition using 3 scoring systems among outpatients with heart failure: a comparison with body mass index. *JACC Heart Fail* 2018;6:476–486.

9. Lin H, Zhang H, Lin Z, Li X, Kong X, Sun G. Review of nutritional screening and assessment tools and clinical outcomes in heart failure. *Heart Fail Rev* 2016;21:549–565.

10. Narumi T, Arimoto T, Funayama A, Kadowaki S, Otaki Y, Nishiyama S, et al. Prognostic importance of objective nutritional indexes in patients with chronic heart failure. *J Cardiol* 2013;62:307–313.

11. Cheng Y-I, Sung S-H, Cheng H-M, Hsu P-F, Guo C-Y, Yu W-C, et al. Prognostic nutritional index and the risk of mortality in patients with acute heart failure. *J Am Heart Assoc* 2017;6:e004876.

12. Gentile F, Sciarrone P, Zamora E, De Antonio M, Santiago E, Domingo M, et al. Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. *Eur J Prev Cardiol* 2020;2047487320927610:28:948–955.

13. Bartko PE, Heiztiger G, Pavo N, Heiztiger M, Spinka G, Prausmüller S, et al. Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study. *BMJ* 2021;373:n1421.

14. McDonagh TA, Metra M, Adamo M, Gardiner RS, Baumbach A, Böhm M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;42:3599–3726.

15. Chen Q-J, Qu H-J, Li D-Z, Li X-M, Zhu J-J, Xiang Y, et al. Prognostic nutritional index predicts clinical outcomes in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Sci Rep* 2017;7:3285.

16. Chan AWH, Chan SL, Wong GLH, Wong VWS, Chong CCN, Lai PBS, et al. Prognostic nutritional index (pni) predicts tumor recurrence of very early/early stage hepatocellular carcinoma after surgical resection. *Ann Surg Oncol* 2015;22:4138–4148.

17. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. *J Am Soc Echocardiogr* 2019;32:1–64.

18. Oreopoulos A, Ezekowitz JA, McAlister FA, Kalantar-Zadeh K, Fidarsov GC, Norris CM, et al. Association between direct measures of body composition and prognostic factors in chronic heart failure. *Mayo Clin Proc* 2010;85:609–617.

19. Farré N, Aranyó J, Enjuanes C, Verdú-Rotell JM, Ruiz S, Gonzalez-Robledo G, et al. Differences in neurohormonal activity partially explain the obesity paradox in patients with heart failure: the role of sympathetic activation. *Int J Cardiol* 2015;181:120–126.

20. Wolk R, Bertole M, Singh P, Brooks MM, Pratley RE, Frye RL, et al. Prognostic value of adipokines in predicting cardiovascular outcome: explaining the obesity paradox. *Mayo Clin Proc* 2016;91:858–866.

21. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. *Lancet* 2000;356:930–933.

**Online supplementary material**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Conflict of interest**

The authors declare that they have no relevant conflict of interest.

DOI: 10.1002/jcsm.12980
22. Banack HR, Stokes A. The “obesity paradox” may not be a paradox at all. *Int J Obes (Lond)* 2017;41:1162–1163.
23. Kalantar-Zadeh K, Anker SD, Horwich TB, Fonarow GC. Nutritional and anti-inflammatory interventions in chronic heart failure. *Am J Cardiol* 2008;101:89E–103E.
24. King D, Smith ML, Chapman TJ, Stockdale HR, Lye M. Fat malabsorption in elderly patients with cardiac cachexia. *Age Ageing* 1996;25:144–149.
25. Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. *Eur Heart J* 1999;20:683–693.
26. Rahman A, Jafry S, Jeejeebhoy K, Nagpal AD, Pisani B, Agarwala R. Malnutrition and cachexia in heart failure. *JPEN J Parenter Enteral Nutr* 2016;40:475–486.
27. Sze S, Pellicori P, Zhang J, Weston J, Clark AL. The impact of malnutrition on short-term morbidity and mortality in ambulatory patients with heart failure. *Am J Clin Nutr* 2021;113:695–705.
28. Arques S, Ambrosi P. Human serum albumin in the clinical syndrome of heart failure. *J Card Fail* 2011;17:451–458.
29. Omran ML, Morley JE. Assessment of protein energy malnutrition in older persons, part II: laboratory evaluation. *Nutrition* 2000;16:131–140.
30. González Madroño A, Mancha A, Rodríguez FJ, de Ulibarri JI, Culebras J. The use of biochemical and immunological parameters in nutritional screening and assessment. *Nutr Hosp* 2011;26:594–601.
31. Anker SD, von Haehling S. The obesity paradox in heart failure: accepting reality and making rational decisions. *Clin Pharmacol Ther* 2011;90:188–190.
32. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. *J Cachexia Sarcopenia Muscle* 2021;12:2259–2261.